SureTrader SureTrader
Home > Boards > US Listed > Medical - Drugs >

RXI Pharmaceuticals Corp (RXII)

RXII RSS Feed
Add RXII Price Alert      Hide Sticky   Hide Intro
Moderator: Inoviorulez
Search This Board:
Last Post: 9/28/2016 10:17:18 PM - Followers: 138 - Board type: Free - Posts Today: 0

About RXi Pharmaceuticals

RXi Pharmaceuticals Corporation (OTC: RXII) is a biotechnology company focused on discovering, developing and commercializing innovative therapies based on its proprietary, next-generation RNAi platform.  Therapeutics that use RNA interference, or "RNAi," have great promise because of their ability to "silence," or down-regulate, the expression of a specific gene that may be overexpressed in a disease condition.  Building on the pioneering work of scientific founder and Nobel Laureate Dr. Craig Mello, RXi's first RNAi product candidate, RXI-109, entered into RXi's first human clinical trial in 2012.  RXI-109 targets connective tissue growth factor (CTGF), a key regulatory of fibrosis and scar formation, and is initially being developed to reduce or inhibit scar formation in the skin following surgery.
 

 



RXi Pharmaceuticals Corp., has received patent approval for their new experimental breast cancer vaccine which became part of the company's arsenal after acquiring Apthera Inc. in April of this year.
The specific patents in question regard using the vaccine NeuVax with the drug Herceptin which is used in women to slow the production of the HER2 protein in tumors, while NeuVax attempts to make the body's immune system fight off cancerous cells.
According to The Telegram:
"The patents also cover using NeuVax in patients not eligible for Herceptin treatment."
With their patent in place the company plans to begin human tests in early 2012.
According to RXi the patents were developed by Dr. George E. Peoples, director of the Cancer Vaccine Development Program for the U.S. Military Cancer Institute and RXi is leasing the patents for their own work.
 

 



This May, RXi Pharmaceuticals Corp. observed two momentous events: The biotechnology company completed its spinoff from Galena Biopharma Inc., and Dr. Geert Cauwenbergh took the helm as president and chief executive officer. The small company's first product, an anti-scarring medication called RXI-109, entered clinical trials this year, and is based on the pioneering work in RNA interference of RXi scientific founder and Nobel Laureate Dr. Craig C. Mello. Dr. Cauwenbergh came to RXi after a long career in pharmaceuticals, most recently as president and chief executive officer of a company he founded, Barrier Therapeutics. What attracted you to come to Worcester? "It was the technology, well, the technology and the chemistry with these people. They're very bright." As a publicly traded company, how do you reconcile the needs of the investors, which are sometimes a short-term desire for profits, with the needs of medical research, which sometimes takes years? "Through business development. Basically what you do as a small biotech is you try to create a big network with people who have interest in various stages of development. ... In two or three years they get antsy and they want to cash in, but at that point in time there will be and there is already a network of business development contacts in place where you can for instance get nondiluted money without having to raise money and go back to the stock market and shareholders by making regional deals or geographic deals ...

NEWS

June 9, 2015 RXi Pharmaceuticals Strengthens Intellectual Property Portfolio for Novel RNAi Platform

http://finance.yahoo.com/news/rxi-pharmaceuticals-strengthens-intellectual-property-110200033.html

Dec 17, 2014 RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301

http://finance.yahoo.com/news/rxi-pharmaceuticals-announces-sustained-effect-120200746.html

Press Releases
RXi Pharmaceuticals to Present at Biotech Showcase™ 2013 - December 19, 2012
RXi Pharmaceuticals Announces Initiation of Second Double-Blind Vehicle Controlled Phase 1 Study With Its Anti-Scarring Compound, RXI-109 - December 5, 2012
RXi Pharmaceuticals Announces Pharmacokinetic Results of its Single Dose Phase 1 Study with RXI-109 in Healthy Volunteers - November 15, 2012
RXi Pharmaceuticals Reports Financial Results for the Third Quarter of 2012 - November 14, 2012
RXi Pharmaceuticals to Present at 12th Annual Biotech Symposium - October 16, 2012
RXi Pharmaceuticals Awarded NCI SBIR Funding to Advance Self-Delivering RNAi Technology - October 4, 2012
RXi Pharmaceuticals to Present at 11th Annual BIO Investor Forum - October 2, 2012
RXi Pharmaceuticals Announces Completion of Dosing in Phase 1 Trial for RXI-109 Program - September 24, 2012
RXi Pharmaceuticals Reports Financial Results for the Second Quarter of 2012 - August 15, 2012
RXi Pharmaceuticals Appoints Jeannette Graf MD and Leroy Young MD to its Scientific Advisory Board - July 13, 2012
 
Share Statistics
Avg Vol (3 month)3: 215,443
Avg Vol (10 day)3: 145,371
Shares Outstanding5: 338m
Float: 53.34M
% Held by Insiders1: 9.01%
% Held by Institutions1: 0.50%
 



http://www.rxipharma.com/

 
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
RXII
Current Price
Volume:
Bid Ask Day's Range
SureTrader
PostSubject
#3640  Sticky Note Rxi Pharmaceuticals (RXII) Research Report 2016 Inoviorulez 06/19/16 09:15:20 AM
#3935   The fact that Geert hasn't bought a single Titan V 09/28/16 10:17:18 PM
#3934   Edison Research values the Samcyprone pipe at $111M. sabaidii2 09/28/16 05:00:30 PM
#3933   One way they could raise cash without giving Titan V 09/28/16 03:19:06 PM
#3932   I think they view Samcyprone as a collaboration sabaidii2 09/28/16 01:03:01 AM
#3931   Interesting point. I think they view Samcyprone as Titan V 09/27/16 10:33:37 PM
#3930   Today's (9/27/2016) presentation: sabaidii2 09/27/16 09:44:02 PM
#3929   Guess that Merger or Future data must not InternetForumUser 09/26/16 02:08:37 PM
#3928   RXI is an illiquid stock. Price movement on sabaidii2 09/23/16 04:08:01 PM
#3927   Share price continues down? Slow bleeding until November? BioPharma 09/23/16 11:54:29 AM
#3926   I agree with you. For scar trials, cohort BioPharma 09/19/16 10:03:49 PM
#3925   According to past updates, do you think the sabaidii2 09/19/16 05:33:26 PM
#3924   According to past updates, do you think the BioPharma 09/19/16 05:15:19 PM
#3923   Correct. sabaidii2 09/19/16 12:18:42 PM
#3922   When RXi attends so many conferences, does that BioPharma 09/19/16 09:41:38 AM
#3921   RXi Pharmaceuticals to Present at the 16th Annual Inoviorulez 09/19/16 07:09:49 AM
#3920   Both MirImmune and Thera Neuropharma are privately held, The Other Guy 09/16/16 01:32:32 PM
#3919   1) "In Cavendish Global Health Impact Forum news sabaidii2 09/15/16 10:24:39 PM
#3918   In 9th Annual BioPharm America™ Conference news it BioPharma 09/15/16 10:08:40 PM
#3917   1) Will RXI merge with MirImmune, Inc. or sabaidii2 09/15/16 09:58:28 PM
#3916   The Cavendish Global Health Impact Forum taking place BioPharma 09/15/16 09:32:37 PM
#3915   Presentation from today's BioPharm America conference on the The Other Guy 09/15/16 04:56:09 PM
#3914   Short interest has come down because A.) RXII Inoviorulez 09/13/16 12:27:49 AM
#3912   You tell me. You have all the answers. The Other Guy 09/12/16 06:41:40 PM
#3911   Which means what? sabaidii2 09/12/16 06:18:09 PM
#3910   Short interest down 3,200 shares as of 8/31 The Other Guy 09/12/16 04:10:05 PM
#3909   I have found that Tamara is not the The Other Guy 09/12/16 09:10:06 AM
#3908   RXi Pharmaceuticals to Present at the 4th Targeting Inoviorulez 09/12/16 08:00:34 AM
#3907   I got it off Stocktwits , a guy East Texas 09/10/16 08:16:42 PM
#3906   The Other Guy, you could have also simply sabaidii2 09/09/16 10:06:10 PM
#3905   Wouldn't a merger require a public filing? The Other Guy 09/09/16 02:20:56 PM
#3904   Sabadii you may be right as well. We Inoviorulez 09/09/16 02:07:47 AM
#3903   Wow if that's true either they are updating Inoviorulez 09/09/16 02:07:04 AM
#3902   I'm going to e-mail them and see if East Texas 09/08/16 11:22:30 PM
#3901   RXI's address is: sabaidii2 09/08/16 11:19:20 PM
#3900   What's up with this?http://www.loopnet.com/Listing/16054628/257-Simarano-Drive- East Texas 09/08/16 09:45:48 PM
#3899   Translation.....no m&a...and things are getting quite desperate. Hypocrates 09/08/16 02:20:48 PM
#3898   RXi Pharmaceuticals Corporation Selected to Present at Cavendish Inoviorulez 09/07/16 05:42:58 PM
#3897   RXi Pharmaceuticals to Present at the 9th Annual The Other Guy 09/06/16 09:27:38 AM
#3896   Could be the company selling to raise operating The Other Guy 09/02/16 10:06:13 AM
#3895   "Big hands lower the price and take out sabaidii2 09/01/16 06:27:14 PM
#3894   Big hands lower the price and take out BioPharma 09/01/16 05:44:32 PM
#3893   Why today PPS down so much? No bad BioPharma 09/01/16 05:28:08 PM
#3892   I think if and when cosmetoceutical testing comes Titan V 09/01/16 04:20:32 PM
#3891   So frustrating, always hearing good improvement, something new, cinders118 09/01/16 04:13:04 PM
#3890   PPS has been tightly traded within a nickel The Other Guy 08/31/16 07:16:41 PM
#3889   "But to be fair, Rxi hasn't delivered when Titan V 08/30/16 07:33:16 PM
#3888   Can't say for sure but feels like it's sabaidii2 08/30/16 07:21:40 PM
#3887   Can't say for sure but feels like it's Titan V 08/30/16 06:07:39 PM
#3886   Interesting read. Where do you think RXII is The Other Guy 08/29/16 12:53:11 PM
#3885   This is a must read. Enjoy and educate Titan V 08/28/16 01:54:45 PM
PostSubject